Article

Lawsuit against health insurers granted class-action status

A federal appeals court in Atlanta has confirmed class-action status for a lawsuit alleging that six health insurers had systematically underpaid 900,000 active and retired physicians.

Related Videos
1 expert in this video
1 expert is featured in this series.
1 expert is featured in this series.
Anna Myers, CNP, answers a question during a Zoom video interview
Related Content
ARANOTE substudy highlights benefits of darolutamide in Black men
April 28th 2025

ARANOTE substudy highlights benefits of darolutamide in Black men

Benjamin P. Saylor
The investigators reported that treatment with darolutamide reduced the risk of radiological progression or death by 49% in Black men.
Pearls & Perspectives: Martin Kathrins, MD, on MED3000 and learning from failed trials
April 28th 2025

Pearls & Perspectives: Martin Kathrins, MD, on MED3000 and learning from failed trials

Amy M. Pearlman, MD Martin Kathrins, MD
Kathrins discusses the intricacies of leading a clinical trial and why "negative" trials are important to informing care strategies.
Skyler Howell, MD | Credit: X.com
April 28th 2025

AUA 2025: GLP-1 RAs could improve sperm count in overweight men

Patrick Campbell
New research reveals GLP-1 receptor agonists may enhance sperm counts in overweight men.
Speaking of Urology: Melissa Kaufman, MD, on AUA’s new guideline on genitourinary syndrome of menopause
April 28th 2025

Speaking of Urology: Melissa Kaufman, MD, on AUA’s new guideline on genitourinary syndrome of menopause

Melissa Kaufman, MD, PhD, FACS
In this episode, guideline chair Melissa Kaufman, MD, PhD, FACS, highlights key points from the new AUA GSM guideline and illustrates its impact for clinical management of this condition.
Stephen J. Freedland, MD
April 28th 2025

Most men in EMBARK trial recover T levels following treatment suspension

Benjamin P. Saylor
More than 80% of patients in both groups had a full recovery of testosterone.
Sandip M. Prasad, MD, MPhil
April 27th 2025

UGN-102 positions itself as an alternative to TURBT for low-grade NMIBC

Benjamin P. Saylor
"I would argue that UGN-102 may very well represent a well-tolerated alternative to TURBT as primary treatment for patients with low-grade disease,” says Sandip M. Prasad, MD, MPhil.
© 2025 MJH Life Sciences

All rights reserved.